Antibody-enzyme conjugates for cancer therapy

Journal of the National Cancer Institute

Volumn 88, Issue 3-4, 1996, Pages 153-165

  Melton, Roger G ^a   Sherwood, Roger F ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Durarned Europe Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOPHENOL DERIVATIVE; ANTINEOPLASTIC AGENT; BETA LACTAMASE; CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIGEN; CEPHALOSPORIN DERIVATIVE; CYTOSINE DEAMINASE; DOXORUBICIN DERIVATIVE; EPIRUBICIN; ETOPOFOS; FLUOROURACIL; GLUTAMIC ACID DERIVATIVE; METHOTREXATE DERIVATIVE; MITOMYCIN C DERIVATIVE; PENICILLIN AMIDASE; PRODRUG; TUMOR ANTIGEN; VINCA ALKALOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER THERAPY; DRUG ACTIVATION; NONHUMAN; REVIEW;

ALKALINE PHOSPHATASE; AMIDOHYDROLASES; AMINOPEPTIDASES; BETA-LACTAMASES; CARBOXYPEPTIDASES; GLYCOSIDE HYDROLASES; HUMANS; IMMUNOCONJUGATES; NITROREDUCTASES; NUCLEOSIDE DEAMINASES; PRODRUGS; RECOMBINANT FUSION PROTEINS;

EID: 0030024847     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.3-4.153     Document Type: Review

References (85)

1. Ehrlich P. The collected papers of P. Ehrlich. London: Peraamon Press, 1960.
2. Pietersz GA, McKenzie IF. Antibody conjugates for the treatment of cancer, Immunol Rev 1992;129:57-80.
3. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975,254:714-6.
4. Fargion S, Camey D, Mulshnie J., Rosen S, Bunn P, Jewitt P, et al. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 1986;40:2633-8.
5. Hand PH, Nuti M, Colcher D, Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 1983;43:728-35.
6. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 1983;130:1462-6.
7. Tagliabue E, Porro G, Barbanti P, Della Tone G, Menard S, Rilke F, et al. Improvement of tumor cell detection using a pool of monoclonal antibodies. Hybridoma 1986,5:107-15.
8. Cobb LM, Humphreys JA, Harrison A. The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltrated spleen. Br J Cancer 1987; 55:53-5.
9. Moshakis V, McIlhinney RA, Neville AM Cellular distribution of monoclonal antibody in human tumours after i.v. administration. Br J Cancer 1981;44:663-9.
10. 131-labeled LL2 (EPB-2) monoclonal antibody. Antibody Immunoconj Radiophar 1991; 4:763-9.
11. Bagshawe KD. The first Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer 1989;60:275-81.
12. Shepherd TA, Jungheim LN. Meyer DL, Starling JJ. A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody beta-lactamase conjugate for the treatment of cancer Bioorg Medicinal Chem Lett 1991;1:21-6.
13. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy with three novel compounds. Eur J Cancer 1991;27:1361-6
14. Begent RH. Recent advances in tumour imaging. Use of radiolabelled monoclonal antibodies. Biochim Biophys Acta 1985;780:151-66.
15. Haenseler E, Esswein A, Vitols KS, Montejano Y, Mueller BM, Reisfeld RA, et al. Activation of methotrexate-alpha-alanine by carboxypeptidase-A-monoclonal antibody conjugate. Biochemistry 1992;31:891-7.
16. Frei E 3d, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988;48:6417-23.
17. Yuan F, Baxter LT, Jam RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-30.
18. 131I-chimeric B72.3 antibody therapy Antibody Immunoconj Radiophar 1993;6.39-46.
19. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Rogers GT, Burke PJ, et al. Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconj Radiophar 1991, 4:915-22.
20. Sharma SK, Bagshawe KD, Melton RG. Immunogenicity of antibody-enzyme conjugates in antibody directed enzyme prodrug therapy. Antibody Immunoconj Radiophar 1991;4:226.
21. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, et al. Antibody directed enzyme prodrug therapy (ADEPT): clinical report Dis Markers 1991;9:233-8
22. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P. Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting 1995,1:17-29.
23. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987;56:531-2.
24. Minton NP, Atkinson T, Bruton CJ, Sherwood RF. The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2 [published erratum appears in Gene 1986:42:353]. Gene 1984;31:31-8.
25. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bisset GM, Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 1990;33:677-81.
26. Springer CJ, Antoniw P, Bagshawe KD, Wilman DE. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des 1991;6:467-79.
27. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG. et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58:700-3.
28. Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, et al. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Marker 1991;9:225-31.
29. Philben VJ, Jakowatz JG, Beatty BG, Vlahos WG, Paxton RJ, Williams LE, et al. The effect of tumor CEA content and tumor size on uptake of indium 111-labeled anti-CEA monoclonal antibody. Cancer 1986;57:571-6.
30. Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer 1990;61:659-62.
31. Blakey DC, Valcaccia BE. East S, Wright AF, Boyle FT, Springer CJ, et al. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys 1993; 22:1-8.
32. Melton RG, Rowland JA, Pietersz GA, Sherwood RF, McKenzie IF. Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. Eur J Cancer 1993;29A:1177-83.
33. Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonie xenograft model. Im J Cancer 1994;57:830-5.
34. Esswein A, Hanseler E, Montejano Y, Vitols KS, Huennekens FM. Construction and chemotherapeutic potential of carboxypeptidase-A/ monoclonal antibody conjugate. Adv Enzyme Regul 1991;31:3-12
35. Keufner U, Lohrmann U, Montejano YD, Vitols KS, Huennekens FM Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides. Biochemistry 1989;28:2288-97.
36. Vitols KS, Montejano YD, Keufner V, Huennekens FM. Selective cytotoxicity of carboxypeptidabe-activated methotrexate-α-peptides. Ptendines 1989;1:65-70.
37. Huennekens E, Esswein A, Vitols KS, Montejano YD, Muller BM, Reisfeld RA, et al. Enhanced cytotoxicity of methotrexate-alpha-alanine in cells treated with carboxypeptidase A/monoclonal antibody conjugate Proc Am Assoc Cancer Res 1991;32:A1911.
38. Perron MJ, Page M. Synthesis of methotrexate prodrugs as an approach for drug targeting. Int J Oncol 1994;5.907-13.
39. Vitols KS, Haag-Zeino B, Baer T, Montejano YD, Huennekens FM. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res 1995;55:478-81.
40. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41:36-51.
41. Smal MA, Dong L, Cheung HT, Asano Y, Escoffier L, Costello M, et al. Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate. Biochem Pharmacol 1995;49:567-74.
42. Senter PD, Schreiber GJ, Hirschberg DL, Ashe SA, Hellstrom KE, Hellstrom I. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989;49:5789-92.
43. Senter PD, Saulmer MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A 1988;85:4842-6.
44. Senter PD, Saulnier MG, Schreiber GJ, Hirshberg DL, Brown JP, Hellstrom I, et al. Anti-tumor effects of antibody-alkaline phosptiatase conjugates in combination with etoposide phosphate. Chemtracts-Organic Chemistry 1989;2:1-4.
45. Senter PD. Activation of prodrugs by antibody-enzyme conjugates a new approach to cancer therapy. FASEB J 1990;4:188-93.
46. Wallace PM, Senter PD. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjug Chem 1991;2:349-52.
47. Haisma HJ, Boven E, Van Muijen M, De Vries R, Pinedo HM. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Immunother 1992;34:343-8.
48. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, et al. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 1990; 50:6944-8.
49. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1991; 42:2062-5.
50. Wang SM, Chern JW, Yeh MY, Ng YC, Tung E, Roffler SR. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992;52:4484-91.
51. Connors TA, Whisson ME. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 1966;210:866-7.
52. Connors TA, Farmer PB, Foster AB, Gilsenan AM, Jarman M, Tisdale MJ. Metabolism of aniline mustard (N,N-di-(2-chloroethyl)aniline). Biochem Pharmacol 1973;22:1971-80.
53. Kyle RA, Costa G, Cooper MR, Ogawa M, Silver RT, Glidewell O, et al. Evaluation of aniline mustard in patients with multiple myeloma. Cancer Res 1973;33:956-60.
54. Haisma HJ, Boven E, van Muijen M, De Jong J, van der Vijgh WJ. Pinedo HM. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer Br J Cancer 1992;66:474-8.
55. Mross K, Maessen P, van der Vigjh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxoribicin and doxorubicin in humans. J Clin Oncol 1988;6:517-26.
56. Andrianomenjanahary S, Dong X, Florent JC, Gaudel G, Gesson JP, Jacquesy JC, et al. Synthesis of novel targeted prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate. Bioorg Medicinal Chem Lett 1992;2:1093-6.
57. Bamias A, Epenetos AA. Two-step strategies for the diagnosis and treatment of cancer with bioconjugates. Antibody Immunoconj Radiophar 1992;5:385-95
58. Kerr DE, Senter PD, Bumett WV, Hirschberg DL, Hellstrom I, Hellstrom KE. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 1990;31:202-6.
59. Vrudhula VM, Senter PD, Fischer KJ, Wallace PM. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate J Med Chem 1993;36:919-23.
60. Bignami GS, Senter PD, Grothaus PG, Fischer KJ, Humphreys T, Wallace PM. N-(4′-Hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate Cancer Res 1992;52:5759-64.
61. Moore RE, Scheuer PJ. Palytoxin: a new marine toxin from coelenterate. Science 1971;172:495-8.
62. +-ATPase. Naunyn Schmiedeberg Arch Pharmacol 1983,323.261-8.
63. Galleni M, Lindberg F, Normark S, Cole S, Honore N, Joris B, et al. Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products. Biochem J 1988;250:753-60
64. Alexander RP, Beeley NR, O'Driscoll M, O'Neill FP, Millican TA, Pratt AJ, et al. Cephalosporin nitrogen mustard carbamate prodrugs for 'ADEPT.' Tetrahedron Lett 1991;32:3269-72.
65. Svensson HP, Kadow JF, Vrudhula VM, Wallace PM, Senter PD Monoclonal antibody beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug Chem 1992;3:176-81.
66. Vrudhula VM, Svensson HP, Kennedy KA, Senter PD, Wallace PM Anti-tumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem 1993;4: 334-40.
67. Meyer DL, Jungheim LN, Mikolajczyk SD, Shepherd TA, Starling JJ, Ahlem CN. Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconjug Chem 1993;3:42-8.
68. Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, et al. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res 1993;53:3956-63.
69. Senter PD, Su PC, Katsuragi T, Sakai T, Cosand WL, Hellstrom I, et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug Chem 1991;2.447-51.
70. O'Boyle K, Senter P, Kuldeep B, Markowitz A, Chun S, Schwartz E, et al. Localisation of L6-cytosine deaminase immunoconjugate in a nude mouse model. Antibody Immunoconj Radiophar 1993;6.68.
71. Kerr DE, Garrigues US, Wallace PM, Hellstrom KE, Hellstrom I, Senter PD. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjug Chem 1993;4:353-7.
72. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL. Intratumoral generation of 5-fluorouracil mediated by an antibody cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 1994;54:2719-23.
73. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ. The nitroreductase enzyme in Walker cells that activates 5-(azyiridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988;37:4671-7.
74. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT) Biochem Pharmacol 1992;44:2289-95.
75. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992;44:2297-301.
76. Neuberger MS, Williams GT, Fox RO Recombinant antibodies possessing novel effector functions. Nature 1984;312:604-8.
77. Melton RG, Boyle JM, Rogers GT, Burke P, Bagshawe KD, Sherwood RF. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods 1993;158:49-56.
78. Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seemann G. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer 1992;65:234-8.
79. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994;54:2151-9.
80. Goshom SC, Svensson HP, Kerr DE, Somerville JE, Semer PD, Fell HP. Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Res 1993;53:2123-7.
81. Rodrigues ML, Presta LG, Kotts CE, Wirth C, Mordenti J, Osaka G, et al. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res 1995;55:63-70.
82. De Sutler K, Fiers W. A bifunctional murine: human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. Mol Immunol 1994;31:261-7.
83. Miyashita H, Karaki Y, Kikuchi M, Fujii I. Prodrug activation via catalytic antibodies Proc Natl Acad Sci U S A 1993;90:5337-40
84. Campbell DA, Gong B, Kochersperger LM, Yonkovich S, Gallop MA, Schultz PG. Antibody-catalyzed prodrug activation. J Am Chem Soc 1994; 116:2165-6.
85. Sehon AH, Carl Prausnitz Memorial Lecture-suppression of antibody responses by chemically modified antigens. Int Arch Allergy Appl Immunol 1991;94.11-20.